QCG
ANTH

Quadrant Capital Group’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

Quadrant Capital Group’s Portfolio ANTH Stock Details ANTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-291
Closed -$1K – 2191
2016
Q4 		$1K Buy
+291
New +$5.04K ﹤0.01% 1910

Other funds holding ANTH

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Quadrant Capital Group's ANTH Position: Q1 2017 in Review

Quadrant Capital Group sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q1 2017, closing a stake of 291 shares — an estimated $1K sold.

Quadrant Capital Group first reported a position in ANTH in Q4 2016 and held it in 1 quarter. The position peaked at $1K in Q4 2016. 60 funds tracked by Wall St. Rank hold ANTH as of Q1 2017.

  • Quadrant Capital Group reported no remaining Anthera Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
  • Quadrant Capital Group sold 291 Anthera Pharmaceuticals, Inc. shares in Q1 2017, an estimated $1K.
  • Quadrant Capital Group first reported a position in Anthera Pharmaceuticals, Inc. in Q4 2016 and held it in 1 quarter.
  • Quadrant Capital Group's Anthera Pharmaceuticals, Inc. position peaked at $1K in Q4 2016.
  • 60 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q1 2017.

Based on Quadrant Capital Group's 13F filing for Q1 2017, filed 10 Apr 2017.